Differences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitis.
David OlivaresCristina AlbaIrene Pérez EncisoValentín RoalesEnrique ReyCarlos TaxoneraPublished in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2020)
UC patients more frequently required adalimumab dose escalation than CD patients. UC patients required optimization earlier than CD patients. More CD patients than UC patients can be dose de-escalated later on during treatment.